A Comprehensive Review on LncRNA LOXL1-AS1: Molecular Mechanistic Pathways of LncRNA LOXL1-AS1 in Tumorigenicity of Cancer Cells

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Aug 13

PMID 39136001

Authors

Saghar Yousefnia

Affiliations

Soon will be listed here.

Abstract

Long non-coding RNAs (lncRNAs) are versatile RNAs that regulate various cellular processes, such as gene regulation, by acting as signals, decoys, guides, and scaffolds. A novel recognized lncRNA, LOXL1-antisense RNA 1 (LOXL1-AS1), is dysregulated in some diseases, including cancer, and acts as an oncogenic lncRNA in many types of cancer cells. Upregulation of LOXL1-AS1 has been involved in proliferation, migration, metastasis, and EMT, as well as inhibiting apoptosis in cancer cells. Most importantly, the malignant promoting activity of LOXL1-AS1 can be mostly mediated by sequestering specific miRNAs and inhibiting their binding to the 3´UTR of their target mRNAs, thereby indirectly regulating gene expression. Additionally, LOXL1-AS1 can decoy transcription factors and proteins and prevent their binding to their regulatory regions, inhibiting their mechanistic activity on the regulation of gene expression and signaling pathways. This review presents the mechanistic pathways of the oncogenic role of LOXL1-AS1 by modulating its target miRNAs and proteins in various cancer cells. Having information about the molecular mechanisms regulated by LOXL1-AS1 in cancer cells can open ways to find out particular prognostic biomarkers, as well as discover novel therapeutic approaches for different types of cancer.

References

Kazemi-Oula G, Ghafouri-Fard S, Mobasheri M, Geranpayeh L, Modarressi M . Upregulation of RHOXF2 and ODF4 Expression in Breast Cancer Tissues. Cell J. 2015; 17(3):471-7. PMC: 4601867. DOI: 10.22074/cellj.2015.8. View

Dey A, Mitra A, Pathak S, Prasad S, Sun Zhang A, Zhang H . Recent Advancements, Limitations, and Future Perspectives of the use of Personalized Medicine in Treatment of Colon Cancer. Technol Cancer Res Treat. 2023; 22:15330338231178403. PMC: 10240881. DOI: 10.1177/15330338231178403. View

Wu C, Zhang J . Long non-conding RNA LOXL1-AS1 sponges miR-589-5p to up-regulate CBX5 expression in renal cell carcinoma. Biosci Rep. 2020; 40(11). PMC: 7670581. DOI: 10.1042/BSR20200212. View

Liu Y, Guo C, Li F, Wu L . LncRNA LOXL1-AS1/miR-28-5p/SEMA7A axis facilitates pancreatic cancer progression. Cell Biochem Funct. 2019; 38(1):58-65. DOI: 10.1002/cbf.3449. View

Bai T, Liu Y, Li B . LncRNA LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells. IUBMB Life. 2019; 71(10):1537-1551. DOI: 10.1002/iub.2075. View

Waters M, Gupta A, Mockenhaupt K, Brown L, Biswas D, Kordula T . RelB acts as a molecular switch driving chronic inflammation in glioblastoma multiforme. Oncogenesis. 2019; 8(6):37. PMC: 6541631. DOI: 10.1038/s41389-019-0146-y. View

Ghafouri-Fard S, Shirvani-Farsani Z, Hussen B, Taheri M . The critical roles of lncRNAs in the development of osteosarcoma. Biomed Pharmacother. 2021; 135:111217. DOI: 10.1016/j.biopha.2021.111217. View

Kim B, Kim S, Lim J, Park S . NCAPH Is Required for Proliferation, Migration and Invasion of Non-small-cell Lung Cancer Cells. Anticancer Res. 2020; 40(6):3239-3246. DOI: 10.21873/anticanres.14305. View

Zhang L, Wan Q, Zhou H . Targeted-regulating of miR-515-5p by LncRNA LOXL1-AS1 on the proliferation and migration of trophoblast cells. Exp Mol Pathol. 2020; 118:104588. DOI: 10.1016/j.yexmp.2020.104588. View

10.

Chen K, Fang H, Xu N . LncRNA LOXL1-AS1 is transcriptionally activated by JUND and contributes to osteoarthritis progression via targeting the miR-423-5p/KDM5C axis. Life Sci. 2020; 258:118095. DOI: 10.1016/j.lfs.2020.118095. View

11.

Li H, Chu J, Jia J, Sheng J, Zhao X, Xing Y . LncRNA LOXL1-AS1 promotes esophageal squamous cell carcinoma progression by targeting DESC1. J Cancer. 2021; 12(2):530-538. PMC: 7738998. DOI: 10.7150/jca.51136. View

12.

Carter J, Ang D, Sim N, Budiman A, Li Y . Approaches to Identify and Characterise the Post-Transcriptional Roles of lncRNAs in Cancer. Noncoding RNA. 2021; 7(1). PMC: 8005986. DOI: 10.3390/ncrna7010019. View

13.

He L, Zhang C, He W, Xu M . The emerging role of ectodermal neural cortex 1 in cancer. Sci Rep. 2024; 14(1):513. PMC: 10766627. DOI: 10.1038/s41598-023-50914-7. View

14.

Kinehara Y, Nagatomo I, Koyama S, Ito D, Nojima S, Kurebayashi R . Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells. JCI Insight. 2018; 3(24). PMC: 6338389. DOI: 10.1172/jci.insight.123093. View

15.

Asadi M, Hassani M, Kiani S, Sabaie H, Moslehian M, Kazemi M . The Perspective of Dysregulated LncRNAs in Alzheimer's Disease: A Systematic Scoping Review. Front Aging Neurosci. 2021; 13:709568. PMC: 8490871. DOI: 10.3389/fnagi.2021.709568. View

16.

Guo T, Peng S, Liu D, Li Y . Long Non-coding RNA LOXL1-AS1 Facilitates Colorectal Cancer Progression via Regulating miR-1224-5p/miR-761/HK2 Axis. Biochem Genet. 2022; 60(6):2416-2433. DOI: 10.1007/s10528-022-10226-3. View

17.

Fayazi Hosseini N, Manoochehri H, Khoei S, Sheykhhasan M . The Functional Role of Long Non-coding RNA UCA1 in Human Multiple Cancers: a Review Study. Curr Mol Med. 2020; 21(2):96-110. DOI: 10.2174/1566524020666200619124543. View

18.

Long B, Li N, Xu X, Li X, Xu X, Liu J . Long noncoding RNA LOXL1-AS1 regulates prostate cancer cell proliferation and cell cycle progression through miR-541-3p and CCND1. Biochem Biophys Res Commun. 2018; 505(2):561-568. DOI: 10.1016/j.bbrc.2018.09.160. View

19.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

20.

Crump L, Wyatt G, Rutherford T, Richer J, Porter W, Lyons T . Hormonal Regulation of Semaphorin 7a in ER Breast Cancer Drives Therapeutic Resistance. Cancer Res. 2020; 81(1):187-198. PMC: 7878309. DOI: 10.1158/0008-5472.CAN-20-1601. View